^
CANCER:

Ovarian Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
BRCA1 mutation
Ovarian Cancer
rucaparib
Sensitive
:
A1
ASCO.org - 4 days - (New A2)
BRCA2 mutation
Ovarian Cancer
rucaparib
Sensitive
:
A1
ASCO.org - 4 days - (New A2)
BRCA1 mutation
Ovarian Cancer
olaparib
Sensitive
:
A1
ASCO.org - 4 days - (New A2)
BRCA2 mutation
Ovarian Cancer
olaparib
Sensitive
:
A1
ASCO.org - 4 days - (New A2)
BRCA1 mutation
Ovarian Cancer
niraparib
Sensitive
:
A1
ASCO.org - 4 days - (New A2)
BRCA2 mutation
Ovarian Cancer
niraparib
Sensitive
:
A1
ASCO.org - 4 days - (New A2)
HRD
Ovarian Cancer
niraparib
Sensitive
:
A1
ASCO.org - 4 days - (New A2)
HRD
Ovarian Cancer
rucaparib
Sensitive
:
A2
ASCO.org - 4 days - (New A2)
FOLR1 overexpression
Ovarian Cancer
IMGN 853
Sensitive
:
B
IGCS 2022 - 2 weeks - (New C3)
FOLR1 expression
Ovarian Cancer
IMGN 853
Sensitive
:
B
IGCS 2022 - 2 weeks - (New C3)
BRCA1 mutation
Ovarian Cancer
BAY 1895344
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C4)
DDR
Ovarian Cancer
BAY 1895344
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C3)
FOLR1 positive
Ovarian Cancer
bevacizumab + IMGN 853
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C3)
HER-2 overexpression
Ovarian Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
D
IGCS 2022 - 2 weeks - (New D)
HRD
Ovarian Cancer
bevacizumab + olaparib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
HRD
Ovarian Cancer
olaparib
Sensitive
:
B
ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation
Ovarian Cancer
bevacizumab + olaparib + durvalumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib + durvalumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
HRD + BRCA2 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HRD + BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ALPP expression
Ovarian Cancer
anti-ALPP CAR-T cells
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
TGFB1-L
Ovarian Cancer
CORT125134
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
NR3C1 overexpression
Ovarian Cancer
CORT125134
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Ovarian Cancer
niraparib
Sensitive
:
A1
BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Ovarian Cancer
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Ovarian Cancer
pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Ovarian Cancer
topotecan
Sensitive
:
A1
No biomarker
Ovarian Cancer
carboplatin + micellar paclitaxel
Sensitive
:
A1
No biomarker
Ovarian Cancer
bevacizumab
Sensitive
:
A1
No biomarker
Ovarian Cancer
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Ovarian Cancer
trabectedin
Sensitive
:
A1
No biomarker
Ovarian Cancer
olaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
pamiparib
Sensitive
:
A1
BRCA1 mutation
Ovarian Cancer
pamiparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
rucaparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Ovarian Cancer
bevacizumab-maly
Sensitive
:
A1
No biomarker
Ovarian Cancer
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Ovarian Cancer
CT-P16 (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Ovarian Cancer
docetaxel
Sensitive
:
A2
No biomarker
Ovarian Cancer
carboplatin + docetaxel
Sensitive
:
A2
No biomarker
Ovarian Cancer
ifosfamide
Sensitive
:
A2
No biomarker
Ovarian Cancer
5-fluorouracil
Sensitive
:
A2
No biomarker
Ovarian Cancer
leucovorin calcium
Sensitive
:
A2
No biomarker
Ovarian Cancer
oxaliplatin
Sensitive
:
A2
No biomarker
Ovarian Cancer
capecitabine
Sensitive
:
A2
No biomarker
Ovarian Cancer
leuprolide acetate
Sensitive
:
A2
No biomarker
Ovarian Cancer
exemestane
Sensitive
:
A2
No biomarker
Ovarian Cancer
cisplatin + gemcitabine
Sensitive
:
A2
No biomarker
Ovarian Cancer
cyclophosphamide
Sensitive
:
A2
No biomarker
Ovarian Cancer
pemetrexed
Sensitive
:
A2
No biomarker
Ovarian Cancer
paclitaxel
Sensitive
:
A2